IMNN Reports Strong Enrollment Momentum
IMNN sees strong enrollment in phase 3 trial
Story updates
01:00:40 PM UTC
SquawkNews
IMNN Imunon reports strong enrollment momentum in phase 3 ovation 3 trial of imnn-001 in advanced ovarian cancer Imunon - reports enrollment rate exceeding forecast in ovation 3 trial - Projects enrollment completion in Q2 2029 for ovation 3 trial - Imnn-001 demonstrates favorable safety profile with no serious immune-related adverse events
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.